Navigation Links
Celleration Inc. Announces Award-Winning Clinical Results to Reduce Unfavorable Deep Tissue Injury Outcomes

EDEN PRAIRIE, Minn., March 3, 2011 /PRNewswire/ -- Celleration Inc., a privately held medical device company focused on developing and commercializing therapeutic ultrasound healing technologies, announced the release of award-winning clinical results at the 2011 National Pressure Ulcer Advisory Panel (NPUAP) Biannual meeting in Las Vegas using MIST® Ultrasound Healing Therapy. The clinical results using MIST Therapy to treat deep tissue injuries(DTI), a form of pressure ulcer or bed sore, were so compelling that the poster was awarded NPUAP's top award for contribution to the field of pressure ulcer research.

The retrospective analysis was conducted at Central Baptist Hospital in Lexington, Kentucky and included 85 patients with a total of 127 deep tissue injuries.  The control group received standard of care, while the treatment group added MIST Therapy to the standard of care.  In the MIST Therapy group 80% demonstrated a favorable outcome, while only 22% of the control group demonstrated a favorable outcome. There was a complete reversal of favorable to unfavorable outcomes between the two groups.  Joyce Black, Associate Professor in the College of Nursing at the University of Nebraska Medical Center and Past President of the NPUAP states, "Deep tissue injury is recognized today as the cause of some of the worse pressure ulcers we see. We had come to believe that there was not much we could do to reverse the tissue loss, but the Central Baptist data should cause all of us to rethink our treatments for DTI."

MIST Therapy is a noncontact, low frequency ultrasound that is delivered through a saline mist.  Unlike conventional wound treatments that are limited to treating the surface, MIST Therapy delivers energy deep into the wound bed to rescue injured cells and minimize tissue loss through reducing inflammation and promoting the body's normal healing process.  "We are very pleased with the results of MIST Therapy in treating deep tissue injuries and the ability of MIST to provide a treatment solution where none has previously existed," stated Mark Wagner, CEO of Celleration.  

A deep tissue injury (DTI) is a type of pressure ulcer that results in injury deep below the surface, but is not visible until days later. The injury then progresses very rapidly to a deep, open wound called a Stage III or IV pressure ulcer, which is considered an unfavorable outcome.  DTI's are a common occurrence in US hospitals with average prevalence rates of 7% to 9%.  In 2008, the Center for Medicare Services (CMS) stopped paying for hospital-acquired conditions they felt were the results of poor quality care, commonly known as "never events".  Stage III and IV pressure ulcers, a common outcome of deep tissue injuries, are included on the list of "never events".

For more information go to

SOURCE Celleration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Celleration, Inc. Announces Close of $8 Million Series E Financing
2. Insmed Announces European Medicines Agency Acceptance of Its Pediatric Investigation Plan for ARIKACE™ in the Cystic Fibrosis Pseudomonas Indication
3. Kendle Announces Fourth Quarter and Full-Year 2010 Results
4. InstaCare Announces Receipt of Technology and Patent Value Analysis Penned by Joseph Wolf, Ph.D and William Walling, CFA
5. Naviscan Announces European Launch of Positron Emission Mammography
6. CVS Caremark Announces Agreement With ActiveHealth Management for Evidence-Based Clinical Decision Support
7. Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takedas DEXILANT®
8. Sangamo BioSciences Announces Presentation at the Cowen and Company 31st Annual Health Care Conference
9. An Easier Way to Breathe Better - ICAP Ocean Tomo Announces an Advanced Medical Inhaler Design
10. Perrigo Announces Arrival of the FDA for Reinspection Related to the Allegan Facility Warning Letter
11. Volcano Corporation Announces Webcast of March 9th Analyst Day
Post Your Comments:
(Date:10/12/2015)... New York , October 12, 2015 ... (FMI) delivers key insights on the global vital signs monitoring ... Devices Market: Global Industry Analysis and Opportunity Assessment 2015-2025." The ... at a healthy CAGR of 9.5% and 9.2% in terms ... to factors, regarding which FMI offers major insights in detail ...
(Date:10/12/2015)... Oct. 12, 2015 Beginning October 1, 2015 ... Partner, the fastest growing practice management system for therapists, ... easily converts all patient diagnostic codes from the former ... --> --> Therapy Partner has ... mental health practitioners to easily understand the conversion to ...
(Date:10/12/2015)... , Oct. 12, 2015 Indivior PLC (LON: INDV) ... of Delaware granted the Company,s motion ... Abbreviated New Drug Application (ANDA) No. 205299 to market a ... and naloxone) Sublingual Film (CIII) in the United ... Since August 2013, Indivior has received Paragraph IV certifications ...
Breaking Medicine Technology:
(Date:10/12/2015)... ... October 12, 2015 , ... To help ... its charitable donation to the National Breast Cancer Foundation. The National Breast Cancer ... breast cancer through early detection, education, and support services. , The annual campaign ...
(Date:10/12/2015)... ... October 12, 2015 , ... SQM Group ... a contact channel benchmarking study. Be a part of this insightful ... for improving customer experience, customer journey, contact channel execution and intelligence, workforce optimization, ...
(Date:10/12/2015)... ... ... Holcomb – Kreithen Plastic Surgery and MedSpa, PLLC (“Holcomb – Kreithen”), one of ... Surgery University,” an educational series of mini seminars covering aesthetic and plastic surgery options, ... Saturday, October 24, 2015. , The goal of the event is to provide hands-on ...
(Date:10/12/2015)... ... October 12, 2015 , ... The Asthma and ... Engagement Award by the Patient-Centered Outcomes Research Institute (PCORI) for a new project ... , The project, entitled “Training Patients with Asthma to Understand and Participate in ...
(Date:10/12/2015)... ... October 12, 2015 , ... International law firm Greenberg ... with the U.S. Biomedical Advanced Research and Development Authority (BARDA) reported to be ... ReCell® Autologous Cell Harvesting Device under a U.S. mass casualty preparedness program. ...
Breaking Medicine News(10 mins):